In Brazil, there has been a concerning rise in cases of acute pancreatitis linked to the use of weight loss pens, commonly containing medications from the GLP-1 agonist class. This class of drugs mimics the action of the naturally occurring gut hormone glucagon-like peptide-1 (GLP-1), which helps regulate appetite and blood sugar levels. Earlier this month, the situation came to international attention after the UK issued a warning about similar cases among users of these medications.

Since 2018, the Brazilian National Health Surveillance Agency (Anvisa) has reported at least six suspected deaths and 225 cases of pancreatitis associated with the use of these weight loss injectables. These alarming figures have been gathered following the launch of these products in Brazil, many of which were involved in clinical trials. The drugs in question include semaglutide, liraglutide, lixisenatide, tirzepatide, and dulaglutide, and each has been noted in association with adverse health effects.

These developments raise significant concerns about the safety and monitoring of weight loss medications in Brazil. As health authorities analyze the data, the increasing reports of pancreatitis emphasize the need for rigorous scrutiny of these products. With growing public awareness and international attention on the risks associated with GLP-1 agonists, both consumers and healthcare providers must remain vigilant to mitigate potential health consequences stemming from their use.